Tags

Type your tag names separated by a space and hit enter

Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Diabetes Obes Metab. 2008 Dec; 10(12):1204-11.DO

Abstract

OBJECTIVE

We examined the effects of rosiglitazone treatment on profiles of adipocytokines levels, postprandial insulin and glucose excursion, lipids levels, comparing with those of pioglitazone treatment in patients with type 2 diabetes mellitus (T2DM).

METHODS

Changes in body weight, haemoglobin A(1c)(HbA(1c)), glucose/insulin/C-peptide/free fatty acid (FFA) during 75 g oral glucose tolerance test (OGTT), HDL-/LDL-cholesterol, triglyceride (TG) and adipocytokines [tumour necrosis factor (TNF)-alpha, leptin and adiponectin] were measured in T2DM patients treated with rosiglitazone, 8 mg/day (n = 35), or pioglitazone, 45 mg/day (n = 21), for 3 months.

RESULTS

After rosiglitazone or pioglitazone treatment, HbA(1c)(8.6-7.2 vs. 8.3-6.9%, rosiglitazone vs. pioglitazone), fasting plasma glucose (190-144 vs. 178-140 mg/dl), fasting FFA (729-595 vs. 641-526 microEq/l), mean plasma glucose-OGTT (292-229 vs. 285-233 mg/dl) and mean FFA-OGTT (580-430 vs. 488-377 microEq/l) decreased similarly and all were statistically significant (p < 0.01). The insulinogenic index (DeltaI(0-120)/DeltaG(0-120)) (0.19-0.30 vs. 0.17-0.26) and Matsuda index of insulin sensitivity (2.0-3.1 and 2.7-4.3) increased (p < 0.01) similarly, despite increase in body weight (85-88 vs. 81-84 kg). TNF-alpha (3.8-3.4 vs. 5.2-4.5 pg/ml) decreased (p < 0.05) and adiponectin (6.3-17.8 vs. 7.1-16.4 microg/ml) increased (p < 0.01), while leptin did not change following either treatment. After rosiglitazone treatment, plasma HDL-cholesterol (34-38 mg/dl) and LDL-cholesterol (103-120 mg/dl) increased (p < 0.01), while TGs (177-167 mg/dl) did not change significantly. After pioglitazone treatment, plasma HDL-cholesterol (34-37 mg/dl) increased (p < 0.05), while LDL-cholesterol (104-105 mg/dl) did not change and TGs (153-106 mg/dl) decreased (p < 0.01).

CONCLUSIONS

Rosiglitazone and pioglitazone have similar beneficial effects on glycaemic control insulin sensitivity, insulin secretion and plasma adipocytokine levels. However, pioglitazone has a more beneficial effect on the plasma lipid profile than rosiglitazone.

Authors+Show Affiliations

Department of Medicine, Diabetes Division, University of Texas Health Science Center, San Antonio, TX 78229-3900, USA.No affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

18476983

Citation

Miyazaki, Y, and R A. DeFronzo. "Rosiglitazone and Pioglitazone Similarly Improve Insulin Sensitivity and Secretion, Glucose Tolerance and Adipocytokines in Type 2 Diabetic Patients." Diabetes, Obesity & Metabolism, vol. 10, no. 12, 2008, pp. 1204-11.
Miyazaki Y, DeFronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab. 2008;10(12):1204-11.
Miyazaki, Y., & DeFronzo, R. A. (2008). Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes, Obesity & Metabolism, 10(12), 1204-11. https://doi.org/10.1111/j.1463-1326.2008.00880.x
Miyazaki Y, DeFronzo RA. Rosiglitazone and Pioglitazone Similarly Improve Insulin Sensitivity and Secretion, Glucose Tolerance and Adipocytokines in Type 2 Diabetic Patients. Diabetes Obes Metab. 2008;10(12):1204-11. PubMed PMID: 18476983.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. AU - Miyazaki,Y, AU - DeFronzo,R A, Y1 - 2008/05/12/ PY - 2008/5/15/pubmed PY - 2009/7/28/medline PY - 2008/5/15/entrez SP - 1204 EP - 11 JF - Diabetes, obesity & metabolism JO - Diabetes Obes Metab VL - 10 IS - 12 N2 - OBJECTIVE: We examined the effects of rosiglitazone treatment on profiles of adipocytokines levels, postprandial insulin and glucose excursion, lipids levels, comparing with those of pioglitazone treatment in patients with type 2 diabetes mellitus (T2DM). METHODS: Changes in body weight, haemoglobin A(1c)(HbA(1c)), glucose/insulin/C-peptide/free fatty acid (FFA) during 75 g oral glucose tolerance test (OGTT), HDL-/LDL-cholesterol, triglyceride (TG) and adipocytokines [tumour necrosis factor (TNF)-alpha, leptin and adiponectin] were measured in T2DM patients treated with rosiglitazone, 8 mg/day (n = 35), or pioglitazone, 45 mg/day (n = 21), for 3 months. RESULTS: After rosiglitazone or pioglitazone treatment, HbA(1c)(8.6-7.2 vs. 8.3-6.9%, rosiglitazone vs. pioglitazone), fasting plasma glucose (190-144 vs. 178-140 mg/dl), fasting FFA (729-595 vs. 641-526 microEq/l), mean plasma glucose-OGTT (292-229 vs. 285-233 mg/dl) and mean FFA-OGTT (580-430 vs. 488-377 microEq/l) decreased similarly and all were statistically significant (p < 0.01). The insulinogenic index (DeltaI(0-120)/DeltaG(0-120)) (0.19-0.30 vs. 0.17-0.26) and Matsuda index of insulin sensitivity (2.0-3.1 and 2.7-4.3) increased (p < 0.01) similarly, despite increase in body weight (85-88 vs. 81-84 kg). TNF-alpha (3.8-3.4 vs. 5.2-4.5 pg/ml) decreased (p < 0.05) and adiponectin (6.3-17.8 vs. 7.1-16.4 microg/ml) increased (p < 0.01), while leptin did not change following either treatment. After rosiglitazone treatment, plasma HDL-cholesterol (34-38 mg/dl) and LDL-cholesterol (103-120 mg/dl) increased (p < 0.01), while TGs (177-167 mg/dl) did not change significantly. After pioglitazone treatment, plasma HDL-cholesterol (34-37 mg/dl) increased (p < 0.05), while LDL-cholesterol (104-105 mg/dl) did not change and TGs (153-106 mg/dl) decreased (p < 0.01). CONCLUSIONS: Rosiglitazone and pioglitazone have similar beneficial effects on glycaemic control insulin sensitivity, insulin secretion and plasma adipocytokine levels. However, pioglitazone has a more beneficial effect on the plasma lipid profile than rosiglitazone. SN - 1463-1326 UR - https://www.unboundmedicine.com/medline/citation/18476983/Rosiglitazone_and_pioglitazone_similarly_improve_insulin_sensitivity_and_secretion_glucose_tolerance_and_adipocytokines_in_type_2_diabetic_patients_ L2 - https://doi.org/10.1111/j.1463-1326.2008.00880.x DB - PRIME DP - Unbound Medicine ER -